Defining overactive bladder: epidemiology and burden of disease.
about
How dry is "OAB-dry"? Perspectives from patients and physician expertsFlexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trialsCost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.The temporal relationship between anxiety disorders and urinary incontinence among community-dwelling adults.Effect of caffeine on bladder function in patients with overactive bladder symptomsDarifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.Self-reported urge urinary incontinence (UUI) among older Mexican-American men: risk factors and psycho-social consequencesDevelopment and changes with age of detrusor overactivity in spontaneous hypertensive rats as observed by simultaneous registrations of intravesical and intraabdominal pressures.Do Physical Therapy Interventions Affect Urinary Incontinence and Quality of Life in People with Multiple Sclerosis?: An Evidence-Based Review.PATTERN OF OVERACTIVE BLADDER IN SOUTHEAST NIGERIA.Mirabegron: a Beta-3 agonist for overactive bladder.A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trialsOveractive bladder, differential diagnosis, and clinical utility of fesoterodineCurrent and emerging investigational medical therapies for the treatment of overactive bladder.Impact of overactive bladder on the brain: central sequelae of a visceral pathologyThe bladder-brain connection: putative role of corticotropin-releasing factor.Comparison of the Effects of Vaginal Royal Jelly and Vaginal Estrogen on Quality of Life, Sexual and Urinary Function in Postmenopausal WomenCyclophosphamide-induced bladder inflammation sensitizes and enhances P2X receptor function in rat bladder sensory neurons.Role of fesoterodine in the treatment of overactive bladder.Effect of urgency symptoms on the risk of depression in community-dwelling elderly menSocial, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms.Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.Overactive bladder in Taiwanese women: re-analysis of epidemiological database of community from 1999 to 2001.Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?Management of OAB in those over age 65.Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure.Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events.Efficacy and duration of response to botulinum neurotoxin A (onabotulinumA) as a treatment for detrusor overactivity in women.Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.Overactive Bladder Is Strongly Associated With Frailty in Older Individuals.Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.Persistent detrusor overactivity in rats after relief of partial urethral obstruction.Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.Personal goals and expectations of OAB patients in the UK.Mirabegron.Higher glycosylated hemoglobin levels increase the risk of overactive bladder syndrome in patients with type 2 diabetes mellitus.
P2860
Q24620940-060C12D6-CD95-401D-AF03-587F556EBC71Q26827108-8C232C66-EF66-4CEC-9769-4FDC4FD5C3BCQ31013378-F017FDBD-C72A-4CC7-BD55-80E70C9388D9Q33515909-8B1E87F1-7B51-4716-8B91-1D5D2F5D506EQ33863110-ED91DCBE-6572-4DD3-9DC1-14FF8E7DCEC8Q34542925-473735E8-43E4-46F6-86F1-C95310A52414Q34565865-017B3093-5251-4C84-9BE8-D723CC69E919Q34575850-2A67BA1F-352F-4F6A-BDB2-76A986E6EF1BQ34951065-7EE98EBF-4E53-4F25-950D-DD7DB4B2365CQ35667290-C4AF2740-C4E0-4523-AD18-F6844C518404Q35974833-902F9C28-933E-464F-9BBD-19BAD15127ACQ36006372-E1C2BF78-A842-4B3B-8533-3C270AD2A697Q36160960-A62BFDED-DA64-4612-AB52-41581CDBD451Q36307893-BF5E6569-7389-4B5F-8B80-49EA92065DB4Q36429651-9FE5E616-75BF-434F-807B-FA3E2C5586CAQ36568728-5D957E60-E5B4-481B-B894-C6EE0654FDBFQ36782469-CB275355-7B99-401E-A782-70D379E4BB1EQ36871552-9CAA4DDE-7049-48D2-A281-E39374EEEA97Q37102836-F0102E99-0CE6-413C-A182-D9B61D7C57E3Q37137251-6347C851-11B3-4541-A074-93AF11387652Q37283542-53290965-07DB-405C-A1AD-CDCE35885768Q37316652-4390A39E-BCE3-4416-8DDB-42AA1571D9E0Q37373376-E305B89F-1CEE-4279-9007-516C437711FBQ37879017-0C05F71C-5D23-4856-81D8-718789B17EFEQ37914102-ABD40809-43F9-4501-9383-9FA8D722B006Q37947438-56488A69-CAFA-458B-8E28-CFE7DB803293Q38127155-5C3F168D-303D-4AC4-A0E1-1E1B7E44F136Q38182708-AD629018-E814-4986-8E71-8C37349D3AECQ38248711-CD40101B-B5FE-4F3A-9825-D13CA61C970EQ38545297-F4D5E7F4-34E9-49FF-854B-F77042AB8581Q38689480-EC5868A3-06F6-4AE8-8E0A-D0ED91BB7784Q38711099-74A6668F-3202-444D-9AAA-FEA201067111Q38786937-BBDE71D9-C752-473E-9D0B-34B583D6A962Q38832902-FC17C105-1E64-4FF3-B17B-9F1407717CBEQ39020998-6D64D1D0-1505-4055-99EF-8F3545C3051BQ39261903-7A3C4FBC-98DC-40EB-BB95-EB509D5756EDQ39342723-61E02100-D7DA-408A-841E-988C0358D1D5Q39450842-1031F2F3-3884-4C6C-A7A6-B8D0ED7668E7Q41266128-7B237798-9E68-4ECB-A76D-737856CBB6E1Q45916219-01885098-650D-468F-BFC5-C5FB79995263
P2860
Defining overactive bladder: epidemiology and burden of disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Defining overactive bladder: epidemiology and burden of disease.
@ast
Defining overactive bladder: epidemiology and burden of disease.
@en
type
label
Defining overactive bladder: epidemiology and burden of disease.
@ast
Defining overactive bladder: epidemiology and burden of disease.
@en
prefLabel
Defining overactive bladder: epidemiology and burden of disease.
@ast
Defining overactive bladder: epidemiology and burden of disease.
@en
P1433
P1476
Defining overactive bladder: epidemiology and burden of disease.
@en
P2093
Andrea Tubaro
P356
10.1016/J.UROLOGY.2004.10.047
P407
P433
P577
2004-12-01T00:00:00Z